Tonix Pharmaceuticals Holding Corp.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US8902608541
USD
12.01
-0.19 (-1.56%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
RenovoRx, Inc.
Biofrontera, Inc.
Tonix Pharmaceuticals Holding Corp.
Impel Pharmaceuticals, Inc.
Aytu Biopharma, Inc.
Cingulate, Inc.
GT Biopharma, Inc.
Eterna Therapeutics, Inc.
Iterum Therapeutics Plc
Lipella Pharmaceuticals, Inc.
Lucy Scientific Discovery, Inc.

Why is Tonix Pharmaceuticals Holding Corp. ?

1
Poor Management Efficiency with a low ROE of 0%
  • The company has reported losses. Due to this company has reported negative ROE
2
Positive results in Mar 26
  • NET PROFIT(HY) Higher at USD -87.1 MM
  • RAW MATERIAL COST(Y) Fallen by -70.49% (YoY)
  • CASH AND EQV(HY) Highest at USD 393.11 MM
3
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -65.01%, its profits have fallen by -57.9%
4
High Institutional Holdings at 41.16%
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
  • Their stake has increased by 6.44% over the previous quarter.
5
Underperformed the market in the last 1 year
  • Even though the market (S&P 500) has generated returns of 25.41% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -65.01% returns
stock-recommendationReal-Time Research Report

Verdict Report

How much should you hold?

  1. Overall Portfolio exposure to Tonix Pharmaceuticals Holding Corp. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Tonix Pharmaceuticals Holding Corp. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Tonix Pharmaceuticals Holding Corp.
-65.01%
-1.08
87.67%
S&P 500
25.41%
1.92
13.25%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
69.79%
EBIT Growth (5y)
-186.65%
EBIT to Interest (avg)
-91.98
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.73
Sales to Capital Employed (avg)
0.09
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
41.16%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.70
EV to EBIT
0.28
EV to EBITDA
0.28
EV to Capital Employed
-0.93
EV to Sales
-2.66
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-49.74%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

19What is working for the Company
NET PROFIT(HY)

Higher at USD -87.1 MM

RAW MATERIAL COST(Y)

Fallen by -70.49% (YoY

CASH AND EQV(HY)

Highest at USD 393.11 MM

NET SALES(Q)

Highest at USD 6.88 MM

OPERATING PROFIT MARGIN(Q)

Highest at -595.84 %

-14What is not working for the Company
OPERATING CASH FLOW(Y)

Lowest at USD -129.49 MM

PRE-TAX PROFIT(Q)

At USD -40.19 MM has Fallen at -31.86%

NET PROFIT(Q)

At USD -40.19 MM has Fallen at -31.86%

Here's what is working for Tonix Pharmaceuticals Holding Corp.

Net Sales
At USD 6.88 MM has Grown at 109.9%
over average net sales of the previous four periods of USD 3.28 MM
MOJO Watch
Near term sales trend is extremely positive

Net Sales (USD MM)

Net Sales
Highest at USD 6.88 MM
in the last five periods
MOJO Watch
Near term sales trend is positive

Net Sales (USD MM)

Operating Profit Margin
Highest at -595.84 %
in the last five periods
MOJO Watch
Company's profit margin has improved

Operating Profit to Sales

Cash and Eqv
Highest at USD 393.11 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is improving

Cash and Cash Equivalents

Raw Material Cost
Fallen by -70.49% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Tonix Pharmaceuticals Holding Corp.

Pre-Tax Profit
At USD -40.19 MM has Fallen at -31.86%
over average net sales of the previous four periods of USD -30.48 MM
MOJO Watch
Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit
At USD -40.19 MM has Fallen at -31.86%
over average net sales of the previous four periods of USD -30.48 MM
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (USD MM)

Operating Cash Flow
Lowest at USD -129.49 MM
in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)